Your session is about to expire
← Back to Search
18F-PSMA PET-MRI Imaging for Prostate Cancer
Study Summary
This trial will use two new imaging technologies to see if they can detect prostate cancers that standard MRI couldn't.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: ARM 2 (RP) - 18F-PSMA
- Group 2: ARM 1 (HIFU) - 18F-PSMA
Frequently Asked Questions
How is 18F-PSMA typically implemented to address medical concerns?
"The radiotracer 18F-PSMA is frequently used to reduce abnormally elevated Prostate Specific Antigen (PSA) levels. It can also be deployed in positron emission tomography and as a treatment option for recurrent prostate cancer, or suspected metastasis."
What is the foremost intent of this experiment?
"This trial, which will be assessed over a six-month period following standard HIFU therapy, aims to evaluate the primary endpoint of HIFU. Secondary outcomes include assessing rate of high grade cancer via tumor mapping and repeat prostate biopsy; determining negative biopsy rate post-HIFU treatment; and measuring specificity of hrMRI, F18-PSMA PET, and mpMRI scans for detecting all tumors and metastasis at 6 months follow up."
Has 18F-PSMA been granted authorization by the FDA?
"Our team at Power believes that 18F-PSMA has a safety rating of 2, as we have evidence for its security but not yet proof of efficacy."
Are there any vacancies available for participants in this medical trial?
"Affirmative. The information on clinicaltrials.gov affirms that recruitment for this medical trial is live, having been posted initially on April 6th 2021 and most recently edited June 2nd 2022. This trial requires 80 participants to be gathered from a single site."
What findings have been produced from earlier explorations with 18F-PSMA?
"Presently, 18F-PSMA is the subject of eighteen ongoing studies. Of those trials, none are in Phase 3; however, some 27 different locations across Baltimore and Maryland are researching this medication."
How many participants are engaging in this experiment?
"Affirmative. Details hosted on clinicaltrials.gov demonstrate that this trial is still recruiting participants, with the initial posting being published on April 6th 2021. The latest update was issued June 2nd 2022 and 80 patients are required at a single medical centre for enrollment in this research project."
Share this study with friends
Copy Link
Messenger